Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARa/STAT1 axis

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 195-206

  Ying, Meidan ^a   Zhou, Xinglu ^a   Zhong, Like ^a   Lin, Nengming ^c   Jing, Hui ^a   Luo, Peihua ^a   Yang, Xiaochun ^a   Song, Hua ^b   Yang, Bo ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; RETINOIC ACID; STAT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MORPHOLOGY; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG SYNERGISM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; PYRAZINES; RANDOM ALLOCATION; RECEPTORS, RETINOIC ACID; STAT1 TRANSCRIPTION FACTOR; TRETINOIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874092767     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0433     Document Type: Article

References (49)

1. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113:3655-65.
2. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-93.
3. Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009; 16:84-91.
4. de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007; 6:811-20.
5. Jing Y, Waxman S. The design of selective and non-selective combination therapy for acute promyelocytic leukemia. Curr Top Microbiol Immunol 2007; 313:245-69.
6. Kopf E, Plassat JL, Vivat V, de The H, Chambon P, Rochette-Egly C. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. J Biol Chem 2000; 275:33280-8.
7. Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D, et al. Inhibition of alltrans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog 2011; 50:24-35.
8. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004; 3:59-70.
9. Luo P, Lin M, Li L, Yang B, He Q. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. PLoS One 2011; 6: e27298.
10. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors invivo. Mol Cancer Ther 2004; 3:279-90.
11. Zhou X, Fang Y, Jing H, Zhong L, Luo P, Song H, et al. Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells. Mol Carcinog. 2011 Oct 17. [Epub ahead of print].
12. Fang Y, Zhou X, Lin M, Jing H, Zhong L, Ying M, et al. The ubiquitinproteasome pathway plays essential roles in ATRA-induced leukemia cells G0/G1 phase arrest and transition into granulocytic differentiation. Cancer Biol Ther 2010; 10:1157-67.
13. Ying M, Tu C, Ying H, Hu Y, He Q, Yang B. MSFTZ, a flavanone derivative, induces human hepatoma cell apoptosis via a reactive oxygen species- and caspase-dependent mitochondrial pathway. J Pharmacol Exp Ther 2008; 325:758-65.
14. Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, et al. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med 2009; 47:536-47.
15. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 2007; 13:1516-22.
16. Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, et al. Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Mol Cancer Ther 2009; 8:1995-2006.
17. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, et al. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 1992; 10:1666-73.
18. Khanna-Gupta A, Zibello T, Sun H, Lekstrom-Himes J, Berliner N. C/ EBP epsilon mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut). Proc Natl Acad Sci U S A 2001; 98:8000-5.
19. Morosetti R, Park DJ, Chumakov AM, Grillier I, Shiohara M, Gombart AF, et al. A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation. Blood 1997; 90:2591-600.
20. Park DJ, Chumakov AM, Vuong PT, Chih DY, Gombart AF, Miller WH Jr., et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest 1999; 103:1399-408.
21. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006; 5:596-613.
22. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10:775-83.
23. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14:1333-42.
24. Shang Y, Baumrucker CR, Green MH. The induction and activation of STAT1 by all-trans-retinoic acid are mediated by RAR beta signaling pathways in breast cancer cells. Oncogene 1999; 18: 6725-32.
25. Kolla V, Weihua X, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997; 272:9742-8.
26. Gianni M, Terao M, Fortino I, LiCalzi M, Viggiano V, Barbui T, et al. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 1997; 89:1001-12.
27. Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007; 21:1363-77.
28. Hsu CL, Kikuchi K, Kondo M. Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. Blood 2007; 110:1420-8.
29. Dimberg A, Karlberg I, Nilsson K, Oberg F. Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. Blood 2003; 102:254-61.
30. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood 2002; 99: 2199-206.
31. Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 1999; 96:14807-12.
32. Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal 2009; 7:e005.
33. Rice AM, Sartorelli AC. Inhibition of 20 S and 26 S proteasome activity by lithium chloride: impact on the differentiation of leukemia cells by alltrans retinoic acid. J Biol Chem 2001; 276:42722-7.
34. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23:4776-89.
35. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, Kammer W, et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007; 21:84-92.
36. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14:1649-57.
37. Testa U. Proteasome inhibitors in cancer therapy. Curr Drug Targets 2009; 10:968-81.
38. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011; 10:2034-42.
39. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005; 4:686-92.
40. Baldassarre G, Boccia A, Bruni P, Sandomenico C, Barone MV, Pepe S, et al. Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth Differ 2000; 11:517-26.
41. Konishi Y, Tominaga A. PU.1 is degraded in differentiation of erythrocytes through a proteasome-dependent pathway. DNA Cell Biol 2006; 25:340-5.
42. Pasquini LA, Paez PM, Moreno MA, Pasquini JM, Soto EF. Inhibition of the proteasome by lactacystin enhances oligodendroglial cell differentiation. J Neurosci 2003; 23:4635-44.
43. Guo W, Shang F, Liu Q, Urim L, Zhang M, Taylor A. Ubiquitin-proteasome pathway function is required for lens cell proliferation and differentiation. Invest Ophthalmol Vis Sci 2006; 47:2569-75.
44. Imai F, Yoshizawa A, Fujimori-Tonou N, Kawakami K, Masai I. The ubiquitin proteasome system is required for cell proliferation of the lens epithelium and for differentiation of lens fiber cells in zebrafish. Development 2010; 137:3257-68.
45. Nahreini P, Andreatta C, Prasad KN. Proteasome activity is critical for the cAMP-induced differentiation of neuroblastoma cells. Cell Mol Neurobiol 2001; 21:509-21.
46. Gianni M, Peviani M, Bruck N, Rambaldi A, Borleri G, Terao M, et al. p38alphaMAPK interacts with and inhibits RARalpha: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells. Leukemia 2012; 26:1850-61.
47. Gianni M, Boldetti A, Guarnaccia V, Rambaldi A, Parrella E, Raska I Jr., et al. Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha. Cancer Res 2009; 69: 1016-26.
48. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996; 273:1717-9.
49. Liu D, Scafidi J, Prada AE, Zahedi K, Davis AE III. Nuclear phosphatases and the proteasome in suppression of STAT1 activity in hepatocytes. Biochem Biophys Res Commun 2002; 299:574-80.